From the driver's seat, not so much.
From the outside, smooth is the last word you'd use for the styling.
On sale next spring starting at $42,275, the i3 exudes "car of the future."
The "i" is BMW's designation for its electrified vehicles, meaning electrics and extended-range electrics and gasoline-electric hybrids.
Ballyhooed for several years, most famously in 2011 in connection with the movie Mission Impossible 4: Ghost Protocol, they have seemed just out of reach, too strange to be real and too real to be all that strange.
Now, the i3 and a super-performance, super-pricey i8 sports car are both due to roll into U.S. showrooms next spring. East Coast markets get the i3 in April, then West Coast areas in May, and the i8 should join them by June, BMW says.
5 Best Oil Stocks To Buy For 2015: Danieli & C Officine Meccaniche SpA (DAS)
Danieli & C Officine Meccaniche SpA is an Italy-based company primarily engaged in industrial sector. The Company designs, manufactures, sales and makes installation of machines and plants for the metallurgical industry. The Company's portfolio includes mines; pellet production plants; blast furnaces; direct reduction equipment; machinery for the treatment of scrap metal; steelworks for production of liquid steel; continuous casting machinery for blooms, billets and slabs; rolling mills for long products, seamless tubes and flat products; production lines for welded tubes and flat products; plants for secondary processing, such as peeling, rolling and drawing; forging presses and manipulators; extrusion presses for ferrous and non-ferrous metals; plants for longitudinal and transversal cutting; automation and control systems, and cranes and lifting equipment. It is also active in the production and sale of special steel for automotive, machine tools and railway industry, among others. Advisors' Opinion:- [By Damian Illia]
Crown Castle has acquired recently the privately held company NextG Networks Inc., largest provider of outdoor Distributed Antenna Systems (DAS), with more than 7,000 DAS plus another 1,500 nodes in the pipeline, and over 4,600 miles fiber-optic cable�� transmission rights. Through this addition, the company has improved greatly its DAS network across 26 United States metropolitan areas. As NextG has only 1.7 tenants per network on an average and thus underutilizing its capacity, Crown Castle will increase customers with no integration and rearrangement costs. Another company�� big move was the acquisition of 9,700 wireless towers from AT&T Inc. (T) Located in the top 100 markets in the U. S. T-Mobile is likely to maintain its infrastructure in these towers for the next 10 years. On top of all, the recent conversion of business into a REIT has represented long term benefits for the company in terms of tax savings and enhancing shareholders��wealth.
Hot Managed Healthcare Companies To Own In Right Now: Speedway Motorsports Inc.(TRK)
Speedway Motorsports, Inc., through its subsidiaries, operates as a promoter, marketer, and sponsor of motor sports activities in the United States. The company principally owns and operates Atlanta Motor Speedway, Bristol Motor Speedway, Charlotte Motor Speedway, Infineon Raceway, Kentucky Speedway, Las Vegas Motor Speedway, New Hampshire Motor Speedway, and Texas Motor Speedway racing facilities. The company also provides souvenir merchandising services; food, beverage, and hospitality catering services; and radio programming, production, and distribution services. In addition, it develops electronic media promotional programming; and distributes wholesale and retail racing, and other sports related souvenir merchandise and apparel. Further, the company manufactures and distributes smaller-scale, modified racing cars and parts; and produces and sells an environmentally-friendly micro-lubricant. Speedway Motorsports has a joint venture with International Speedway Corporat ion to produce, market, and sell licensed motorsports collectible and consumer products, primarily trackside event souvenir merchandising. The company was founded in 1959 and is based in Concord, North Carolina.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Speedway Motorsports (NYSE: TRK ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Speedway Motorsports (NYSE: TRK ) , whose recent revenue and earnings are plotted below. - [By Patricio Kehoe]
The motorsports industry is a natural monopoly at the local level, since only one racetrack can hold NASCAR events in each market, and until now, International Speedway has won this battle. Nevertheless, over the past five years, this company has suffered under declining ticket and concession spending, due to a weak demographic fan base located in troubled geographies. Although recent racetrack changes and customer stabilization will leave ISCA well positioned when spending power increases once again, this is bound to happen at a slow pace. However, the distinct properties of each racetrack attract high brand loyalty, and have compelled competitors like Speedway Motorsports Inc. (TRK) to focus business on completely different markets, therefore posing no real threat to ISCA.
Hot Managed Healthcare Companies To Own In Right Now: Supernus Pharmaceuticals Inc (SUPN)
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�� two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.
Supernus�� Late-Stage Neurology Portfolio
SPN-538 is an oral once-daily extended release topiramate product for the treatment of epilepsy. Topiramate is marketed by Johnson & Johnson under the brand name Topamax and is available in a generic form. As of December 31, 2009, Topiramate was available only in immediate release form and is indicated for monotherapy and adjunctive therapy of epilepsy and for the treatment of migraine. It works by enhancing the inhibitory effect of the Gamma-Aminobutyric Acid (GABA) neurotransmitter that regulates neuronal excitability throughout the nervous system, blocking the excitatory effect of the glutamate neurotransmitter, blocking the sodium channel and inhibiting the carbonic anhydrase enzyme.
Epliga is an oral once-daily extended release formulation of oxcarbazepine. As of December 31, 2009, Epliga was in Phase III trials. Oxcarbazepine is marketed by Novartis under the brand name Trileptal and is available in a generic form. Trileptal is indicated for monotherap! y and adjunctive therapy of epilepsy. Oxcarbazepine is an active voltage-dependent sodium channel blocker.
Supernus�� Psychiatry Portfolio
SPN-810 (molindone hydrochloride) is a treatment for impulsive aggression in patients with ADHD. As of December 31, 2009, it was in Phase II. SPN-810 is based on molindone hydrochloride. As of December 31, 2009, the Company had completed four clinical trials for SPN-810, including a Phase IIa trial, in which it tested the safety and tolerability of immediate release molindone hydrochloride in children with ADHD who suffer from serious persistent conduct problems. This open-label, dose-ranging trial randomized 78 children, 6-12 years of age, into one of four treatment groups, which were given four different doses of immediate release molindone hydrochloride, between 10 milligram and 40 milligram per day, depending on weight, three times a day over a six-week treatment period, after 2-5 weeks of titration. SPN-810 was well tolerated in the trial with no clinically meaningful changes in standard hematology, clinical chemistry values, vital signs or electrocardiogram results. SPN-810 also showed improvements on the primary and secondary outcome measures, such as conduct problem and ADHD scales, across all four treatment groups. SPN-812 is a non-stimulant treatment for ADHD. As of December 31, 2009, SPN-812 was in Phase II. SPN-812 is a selective norepinephrine reuptake inhibitor.
Supernus�� Technology Platforms
The Company has a long track record of developing products by applying technologies to known drugs to improve existing therapies and to enable the treatment of new indications. Supernus�� main technology platforms include: Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The Company�� technologies have been used in the approved and marketed products, including Carbatrol (carbamazepine), Equetro (carbamazepine), Adderall XR (mixe! d ampheta! mine salts), Sanctura XR (trospium chloride), Oracea (doxycycline) and Intuniv (guanfacine).
Advisors' Opinion:- [By Monica Gerson]
Supernus Pharmaceuticals (NASDAQ: SUPN) confirmed the FDA approval of its partner's heart blood-pressure treatment. Supernus shares jumped 18.24% to $8.75 in after-hours trading.
- [By Sara Sjolin]
Shares of Supernus Pharmaceuticals (SUPN) �could also be active, after the company jumped 20% after-hours on Monday after a drug on which the firm collaborated received Food and Drug Administration approval.
- [By Monica Gerson]
Supernus Pharmaceuticals (NASDAQ: SUPN) is expected to post a Q4 loss at $0.55 per share on revenue of $7.78 million.
Geron (NASDAQ: GERN) is projected to post a Q4 loss at $0.07 per share on revenue of $350.00 thousand.
Hot Managed Healthcare Companies To Own In Right Now: Digital River Inc.(DRIV)
Digital River, Inc. provides end-to-end global cloud-commerce and marketing solutions. The company offers a range of services that enables its customers to establish an online sales channel. Its services include design, development, and hosting of online stores and shopping carts; store merchandising and optimization; order management; denied parties screening; export controls and management; tax compliance and management; fraud management; digital product delivery via download; physical product fulfillment; subscription management; online marketing, including email marketing; management of affiliate programs; paid search programs; payment processing services; Web site optimization, Web analytics, and reporting; and CD production and delivery services. The company also provides paid search advertising, search engine optimization, affiliate marketing, store optimization, multi-variant testing, and Web analytic and e-mail optimization services. In addition, it offers a range of payment processing services, such as multiple payment methods, fraud management, tax management, cloud-based billing, and other payment optimization services. The company sells its products and services through Internet and direct sales force. It serves software, consumer electronics, and computer and video game product manufacturers, as well as online channel partners, including retailers and affiliates in the United States, Austria, Brazil, China, Germany, Korea, Ireland, Japan, Luxembourg, Mexico, Singapore, Sweden, Taiwan, and the United Kingdom. Digital River, Inc. was founded in 1994 and is headquartered in Minnetonka, Minnesota.
Advisors' Opinion:- [By Seth Jayson]
Digital River (Nasdaq: DRIV ) is expected to report Q2 earnings on July 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Digital River's revenues will expand 0.4% and EPS will wane -85.0%. - [By Alex Planes]
What: Shares of Digital River� (NASDAQ: DRIV ) are trading 8% higher in the afternoon after rocketing to an opening-bell gain of over 11% on Wednesday morning. Investors have cheered Digital River's strong first-quarter earnings and are reacting favorably to respectable (though not strong) guidance issued for the remainder of the fiscal year.
Hot Managed Healthcare Companies To Own In Right Now: Prothena Corporation PLC (PRTA)
Prothena Corporation PLC, incorporated on September 26, 2012, is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion. Its pipeline includes NEOD001, PRX002 and PRX003. The Company�� work in protein misfolding could result in therapies to treat several neurodegenerative diseases, including AL (primary) and AA (secondary) forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002). Its cell adhesion development activities could generate new therapies to treat inflammatory diseases and metastatic cancers (PRX003). The Company�� program, NEOD001, is in Phase 1. In addition to antibodies directed to neo-epitope targets, it is developing antibodies directed to other targets. The Company has generated antibodies against cell adhesion targets expressed on certain pathogenic Th17 immune cells and tumor cells.
The Company�� pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of disease. It is also generating additional antibodies against other targets involved in protein misfolding and cell adhesion for characterization in vivo and in vitro.
NEOD001 for Amyloidosis
NEOD001 is a monoclonal antibody that targets the amyloid that accumulates in both AL and AA forms of amyloidosis. The antibody was designed to not react with normal serum amyloid A and only with the aberrant cleaved form of the protein (amyloid A).
PRX002 for Parkinson�� Disease
The Company has generated antibodies targeting alpha-synuclein that may slow or reduce the neurodegeneration associated with synuclein misfolding and/or transmission. It has tested these antibodies in various cellular and animal models of synuclein-related disease. In a transgenic mouse model of Parkinson�� disease, passive immunization with 9E4, a murine ver! sion of PRX002, reduced the appearance of synuclein pathology, protected synapses and improved performance by the mice in behavioral testing. The humanized antibody product candidate PRX002 has advanced into manufacturing and preclinical testing.
PRX003 for Inflammatory Diseases and Cancers
The Company is developing PRX003, a monoclonal antibody targeting MCAM for the potential treatment of inflammatory diseases and cancers. It has generated monoclonal antibodies that block MCAM-mediated cell adhesion and have been shown to delay relapse and severity of relapse in a mouse model of multiple sclerosis known as experimental autoimmune encephalomyelitis. The Company�� antibodies are being tested in animal models of inflammatory diseases and cancers. Based on early results from these studies, it has identified a clinical candidate, PRX003. It has advanced this antibody into manufacturing and intends to advance this antibody into preclinical testing.
Advisors' Opinion:- [By Lisa Levin]
Prothena Corporation plc (NASDAQ: PRTA) rose 24.40% to $46.23 after the company reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00.
- [By Michael Robinson]
CSD is also tapping into the biotech boom. Another firm that it holds, and we like, is Prothena Corporation PLC (PRTA), a clinical-stage biotechnology firm focused on Parkinson's disease and other neurodegenerative disorders.
Hot Managed Healthcare Companies To Own In Right Now: Cash America International Inc.(CSH)
Cash America International, Inc. provides specialty financial services to individuals primarily in the United States and Mexico. The company operates in three segments: Pawn Lending, Cash Advance, and Check Cashing. The Pawn Lending segment offers pawn loans through its pawn lending locations, which operate under the names Cash America Pawn and SuperPawn in the United States, and Prenda Facil in Mexico. This segment also sells previously-owned merchandise acquired from customers who do not redeem their pawned goods, as well as sells items purchased from third-parties or customers. The Cash Advance segment offers unsecured cash advances in selected lending locations that are operated under the names Cash America Payday Advance and Cashland in the United States; and short-term cash advances over the Internet under the names CashNetUSA in the United States, QuickQuid in the United Kingdom, and DollarsDirect in the Canada and Australia. This segment also involves in arranging loans for customers with independent third-party lenders through a credit services organization program; providing marketing and loan processing services for a third-party bank issued line of credit on certain stored-value debit cards that the bank issues; and purchasing a participation interest in certain line of credit receivables originated by the bank. The Check Cashing segment provides check cashing and other financial services, such as stored-value cards, money orders, and money transfers. This segment operates its check cashing locations under the Mr.Payroll name. As of December 31, 2009, it operated 676 pawn lending locations, including 667 company-owned units and 9 unconsolidated franchised units; 246 cash advance locations; and 120 unconsolidated franchised and 6 consolidated company-owned check cashing locations. The company was founded in 1984 and is headquartered in Fort Worth, Texas.
Advisors' Opinion:- [By Jake L'Ecuyer]
Shares of Cash America International (NYSE: CSH) got a boost, shooting up 9.22 percent to $42.05 after the company reported that it is planning to evaluate separation of online business.
- [By Ben Levisohn]
Upgrades had a big impact on stocks today. Wendy’s (WEN), for instance, gained 4.5% to $8.62 after being upgraded to Buy at Argus, while Cash America (CSH) advanced 3.7% to $44.32 after being upgraded to Market Outperform from Market Perform at JMP Securities. Walgreen (WAG) proved the big winner in the S&P 500 after�Goldman Sachs called the stock a Conviction Buy.
- [By John Udovich]
Despite�a slow global economy and continued high unemployment in many countries, small cap payday or pawn stocks Cash Store Financial Services Inc (NYSE: CSFS), DFC Global Corp (NASDAQ: DLLR) and Cash America International, Inc (NYSE: CSH) have not exactly been performing well since the start of the year. In fact, these three stocks are the worst performers in the payday or pawn loan sector, down 38.5%, down 14.4% and up 4.6%, respectively, since the start of the year.
- [By Monica Gerson]
Cash America International (NYSE: CSH) is expected to report its Q3 earnings at $0.81 per share on revenue of $443.67 million.
Mead Johnson Nutrition Company (NYSE: MJN) is estimated to report its Q3 earnings at $0.80 per share on revenue of $998.82 million.